A 24-week study from Ain Shams University in 80 adolescents with transfusion-dependent beta-thalassaemia and diabetes found that weekly dulaglutide improved glycaemic control and variability more than daily insulin, with no significant weight gain and early signs of reduced iron overload. The first…
Weekly injections of dulaglutide , a GLP-1 receptor agonist already approved for type 2 diabetes, achieved better glycaemic control than daily insulin in adolescents with diabetes caused by transfusion-dependent beta-thalassaemia TDT , according to a study by researchers at Ain Shams University in Egypt published in Diabetologia.
The trial enrolled 80 adolescents aged 10 to 18 whose TDT-induced diabetes was not responding to metformin . Approximately 40 participants were assigned to dulaglutide once a week; the other approximately 40 received daily injections of insulin at standard doses. After 24 weeks of treatment and follow-up, the dulaglutide group showed greater improvements in glycaemic control and glycaemic variability, spent more time in a healthy glucose range, and did not gain significant weight, a contrast with the insulin group. The investigators also reported signs of reduced iron overload and an absence of hypoglycaemia or safety concerns.
The findings were reported on 23 August 2026 by David Nield, with fact-checking by Rachel Garner and editing by Peter Dockrill. The researchers describe the work as the first to assess dulaglutide in adolescents with TDT-induced diabetes, a secondary diabetes distinct from both type 1 and type 2 disease. If the findings hold, a once-weekly injection could replace a daily one in patients who already carry heavy transfusion, chelation, and injection burdens. But the evidence is early, and the published report leaves design details, including randomisation, unstated.
TDT is the severe, transfusion-dependent form of beta-thalassaemia, the inherited haemoglobin disorder in which mutations reduce or abolish synthesis of the beta-globin chain. Affected children develop life-threatening anaemia in infancy and depend on regular red-cell transfusions from early childhood. Transfusions keep them alive, but every unit of donor blood also delivers iron, and the human body has no effective mechanism for excreting the surplus. Over years, iron accumulates in the liver, spleen, heart, and endocrine glands. The pancreas is hit twice: iron deposits directly in the islets, and non-transferrin-bound iron in the circulation generates reactive oxygen species that damage beta-cells. Insulin production falls, and diabetes emerges.
That sequence makes TDT-induced diabetes a secondary diabetes of iron-driven beta-cell destruction, not the autoimmune attack of type 1 diabetes and not the peripheral insulin resistance of early type 2 diabetes. Because transfusion and chelation have transformed survival, children with TDT now live into adolescence and adulthood, and the metabolic complications of iron overload have become the clinical frontier. Diabetes in TDT typically appears in the second decade of life, in patients who are already managing transfusions, chelation, and the sequelae of chronic anaemia.
The distinction matters for treatment. In type 2 diabetes, insulin resistance is the dominant problem and exogenous insulin is one option among several. In TDT diabetes, the problem is a failing beta-cell population, and the conventional second-line treatment after metformin is insulin. The question posed in this study was whether a peptide that amplifies insulin secretion, rather than replacing it, could do the job better.
The study enrolled 80 adolescents, aged 10 to 18, whose TDT-induced diabetes was not responding to metformin. Participants were assigned to one of two treatment groups, with approximately 40 per arm: weekly subcutaneous injections of dulaglutide, or daily injections of insulin at standard doses. Treatment and follow-up ran for 24 weeks. The published account does not state whether participants were randomly allocated, a point taken up below.
The investigators tracked nine categories of outcome:
The headline result came on the two measures of glucose handling. The researchers wrote: "dulaglutide therapy was associated with greater improvements in glycaemic control and variability compared with insulin among adolescents with TDT-induced diabetes." Participants on dulaglutide also spent more time in healthy glucose zones. Unlike the insulin group, the dulaglutide group showed no significant weight gain, a relevant finding in adolescents whose metabolic health is already compromised. The investigators reported signs of reduced iron overload, no risk of hypoglycaemia, and no safety concerns.
The investigators attempted to keep the comparison clean. "Participants were instructed to refrain from substantial changes in their lifestyle habits throughout the study period," they noted. That instruction limits one source of confounding, but it does not establish that the two groups were metabolically comparable at baseline, and it tells readers nothing about adherence to the instruction or to the assigned injections.
The absence of an explicit statement about randomisation is the central limitation of the public record. Random allocation is what makes two groups comparable on average across measured and unmeasured characteristics. Without it, a difference between groups could reflect who was selected for which treatment rather than what the treatment did. In a small study of a rare condition, that risk is not trivial. Baseline differences in body weight, residual beta-cell function, or iron burden could plausibly explain part of the reported advantage.
The published account also provides no statistical details. There are no confidence intervals, no effect sizes, and no measures of precision. The reader can see the direction of the reported differences, but not their magnitude or reliability. That is a description of what the public record supports, not a judgement on the underlying data.
The injection schedules complicate blinding. A once-weekly versus once-daily regimen cannot be easily masked unless a double-dummy design is used, with placebo injections on the intervening days, and the report does not indicate that such a design was employed. Unblinded participants may change behaviour in ways that influence glucose control and weight, which is precisely why the lifestyle instruction is useful. It is a partial safeguard at best.
The authors frame their study accordingly. "It is the first to assess the efficacy of dulaglutide in adolescents with TDT-induced diabetes, providing insight into a promising therapeutic modality for this vulnerable population," they wrote. They also state the limits: "Future larger prospectively registered multicenter studies with extended follow-up are warranted to validate these findings and explore the mechanistic pathways." A 24-week window can capture changes in glucose control, weight, and short-term safety. It cannot establish whether dulaglutide slows the progression of pancreatic damage, alters iron accumulation over years, or changes long-term complication rates. And it cannot separate a drug effect from a selection effect unless the design is randomised.
Dulaglutide is a peptide-based drug with a deliberate design. Native GLP-1 is secreted by intestinal L-cells after meals and potentiates glucose-stimulated insulin secretion, but the enzyme DPP-4 degrades it within minutes. Dulaglutide is a modified GLP-1 sequence fused to the Fc fragment of human immunoglobulin G. The Fc domain engages the neonatal Fc receptor, which recycles the molecule back into the circulation instead of allowing it to be degraded, extending the half-life from minutes to days and permitting one injection per week.
The drug's actions are tied to ambient glucose. When glucose is elevated, it amplifies insulin secretion from beta-cells, suppresses glucagon release, slows gastric emptying, and increases satiety. When glucose is normal, those effects recede, which is why the class carries a low intrinsic risk of hypoglycaemia. The observed absence of hypoglycaemia in the dulaglutide group is coherent with that pharmacology. So is the weight finding: exogenous insulin is anabolic and commonly promotes fat gain, whereas GLP-1 receptor agonists are weight-neutral on average.
The efficacy of dulaglutide in an insulin-deficient state deserves a moment's thought. TDT diabetes is caused by loss of beta-cells, yet a drug that works by amplifying endogenous insulin secretion outperformed exogenous insulin. The most direct interpretation is that these adolescents retained meaningful residual beta-cell function, enough for a glucose-dependent amplifier to act on, and that supporting that residual capacity served them better than replacing it. That interpretation is consistent with the study's inclusion of pancreatic reserve as an outcome. Evidence in type 2 diabetes has pointed to possible preservation of beta-cells by GLP-1-based therapy, though the durability of that effect in humans remains debated, and the current study cannot settle it.
The iron result is harder to explain. Transfusion iron is handled mainly by the liver and the reticuloendothelial system, and systemic iron balance is governed largely by the liver peptide hepcidin , not by the incretin system. A GLP-1 receptor agonist has no established direct role in cellular iron handling. If dulaglutide truly reduces iron overload, the pathway could run through improved metabolic control, altered inflammatory signals from iron-laden tissues, changes in body composition, or an interaction not yet described. The current study does not contain the measurements needed to discriminate among these possibilities, and the authors explicitly leave the mechanism open. Confirmation would require quantitative iron measures, such as serum ferritin and magnetic resonance imaging estimates of liver and cardiac iron, collected alongside glucose and weight data in a prospective study.
Peptide Atlas's internal records quantify how far this study sits from the established literature. The platform's registry file lists 0 registered clinical trials for dulaglutide, and its literature index records 1 PubMed-indexed paper. That single paper is REWIND, "Dulaglutide and cardiovascular outcomes in type 2 diabetes," published in The Lancet on 13 July 2019 PMID 31189511 . The Peptide Atlas reference page for the molecule is at https://peptideatlas.co/peptides/dulaglutide.
REWIND was a large randomised cardiovascular outcomes trial in adults with type 2 diabetes. It demonstrated a lower rate of major adverse cardiovascular events with dulaglutide than with placebo and established the drug's cardiovascular profile in that adult population. It says nothing about adolescents, nothing about secondary diabetes, and nothing about iron overload.
The contrast with the new study is stark. No dulaglutide trial of any kind is registered in the Peptide Atlas file, and no paediatric or thalassaemia-related dulaglutide paper is indexed in its literature record. The Ain Shams study is therefore the only signal in the platform's evidence base for this drug in this indication, and it is a signal from a single two-group comparison of unstated randomisation status. The formal evidence base for dulaglutide in TDT-induced diabetes currently consists of one study.
For clinicians, the immediate situation is unchanged by this study: dulaglutide is approved for type 2 diabetes, so its use in TDT-induced diabetes is off-label. Any prescription in an adolescent with thalassaemia…
Peptides referenced: Dulaglutide, Glucagon, GLP-1.
Related reading: IndexBox Lists US$4,000 UK Peptide Serum Report, No Findings, Seoul seizes 4,155 illegal Wegovy and Mounjaro imports in six months, Energean shares slide 12.3% in 2026 while Brent holds above $92, Oral Wegovy Outruns Foundayo in the First Full Quarter of Oral Competition.